3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
243
Neoplasms
15
Neoplasm Metastasis
12
Carcinoma, Intraductal, Noninfiltrating
11
Breast Diseases
8
Advanced Breast Cancer
8
Breast Neoplasms, Male
7
Breast Carcinoma In Situ
7
Triple Negative Breast Neoplasms
5
Arthralgia
4
Ovarian Neoplasms
3
Neoplasms by Site
3
Breast Cancer Metastatic
3
Uterine Cervical Neoplasms
2
Recurrence
2
Patient Compliance
2
Osteoporosis
2
Obesity
2
Endometrial Neoplasms
2
Breast Neoplasm Female
2
Vitamin D Deficiency
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Skin Diseases
1
Sexual Dysfunctions, Psychological
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Pain
1
Nutrition Disorders
1
Interventions
pembrolizumab
33
Docetaxel
10
Nivolumab
9
Paclitaxel
6
Trastuzumab
5
Gemcitabine
5
Cetuximab
5
Carboplatin
5
Capecitabine
5
Fulvestrant
4
Cyclophosphamide
4
spartalizumab
3
poly ICLC
3
durvalumab
3
avelumab
3
Oxaliplatin
3
Leucovorin
3
Ipilimumab
3
Fluorouracil
3
Cisplatin
3
Biopsy
3
zimberelimab
2
tremelimumab
2
palbociclib
2
obinutuzumab
2
lenvatinib
2
cemiplimab
2
budigalimab
2
Vorinostat
2
Specimen Handling
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
Anastrozole
×
Breast
×
Clear all
NCT05768139
2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled